ABIO实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (4 May 2024 @ 04:00):

ARCA biopharma, Inc., a clinical-stage biopharmaceutical company, develops and commercializes genetically targeted therapies for cardiovascular diseases...

Stats
今日成交量	16 801.00
平均成交量	1.45M
市值	47.29M
EPS	$0 ( 2024-04-24 )
下一个收益日期	( $0 ) 2024-07-19
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-7.76
ATR14	$0.0180 (0.55%)

Insider Trading

Date	Person	Action	Amount	type
2024-01-30	Ma-weaver Jacob	Buy	6 000	Stock option (right to buy)
2024-01-30	Hove Anders D	Buy	6 000	Stock Option (right to buy)
2024-01-30	Mitchell Daniel J	Buy	6 000	Stock Option (right to buy)
2024-01-30	Flynn James P	Buy	6 000	Stock Option (right to buy)
2024-01-30	Conway Robert E	Buy	6 000	Stock Option (right to buy)

INSIDER POWER
98.25
Last 95 transactions
Buy: 2 938 848 \| Sell: 17 694 644

音量相关性

長: 0.11 (neutral)

短: 0.05 (neutral)

Signal:(42.227) Neutral

ARCA Biopharma Inc 相关性

10 最正相关
SCTL	0.977
LABP	0.957
MESO	0.952
MOTNU	0.943
NN	0.94
RMRM	0.933
VFF	0.932
STOK	0.928
AMRB	0.928
SMTC	0.927

10 最负相关
ATHN	-0.937
ARIZ	-0.926
AMD	-0.923
OSIS	-0.918
QQQM	-0.918
QQQ	-0.918
LULU	-0.916
CIFR	-0.916
CYN	-0.915
EZGO	-0.912

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

ARCA Biopharma Inc 相关性 - 货币/商品

0.16
( neutral )

-0.27
( neutral )

0.00
( neutral )

0.17
( neutral )

-0.19
( neutral )

ARCA Biopharma Inc 财务报表

Annual	2023
营收:	$0
毛利润:	$-111 000 (0.00 %)
EPS:	$-0.370

FY	2023
营收:	$0
毛利润:	$-111 000 (0.00 %)
EPS:	$-0.370

FY	2022
营收:	$0
毛利润:	$-114 000 (0.00 %)
EPS:	$-0.640

FY	2021
营收:	$0.00
毛利润:	$0.00 (0.00 %)
EPS:	$-1.390

Financial Reports:

No articles found.

ARCA Biopharma Inc

ARCA biopharma, Inc., a clinical-stage biopharmaceutical company, develops and commercializes genetically targeted therapies for cardiovascular diseases. Its lead product candidates are Recombinant Nematode Anticoagulant Protein c2 (rNAPc2) (AB201), which is in Phase IIb clinical trial for the treatment for COVID-19; and Gencaro (bucindolol hydrochloride), a pharmacogenetically-targeted beta-adrenergic receptor antagonist that has completed Phase IIb trial for the treatment of atrial fibrillation in patients with chronic heart failure. ARCA biopharma, Inc. has a collaboration agreement with LabCorp to develop genetic test for GENETIC-AF clinical trial; and research collaboration with Colorado Prevention Center, the University of Colorado's Academic Research Organization to develop and commercialize Gencaro. The company was incorporated in 2004 and is headquartered in Westminster, Colorado.